Primary Biliary Cholangitis (PBC): Understanding Your Pathology Report

by Stephanie Reid, MD FRCPC
November 18, 2026


Print this article

Primary biliary cholangitis (PBC) is a long-lasting autoimmune disease in which the immune system slowly destroys the small bile ducts inside the liver. It is not cancer. Without treatment, the damage can lead to liver scarring over many years. With treatment, most people with PBC have a normal or near-normal life expectancy.

This article explains what primary biliary cholangitis is, how it is diagnosed, and what pathologists look for when they examine a liver biopsy. It also explains the stage in your report and the treatments now available. PBC was previously called primary biliary cirrhosis. The name was changed because cirrhosis is only a feature of advanced disease, and many people with PBC never reach that stage.

What is primary biliary cholangitis?

The liver makes bile, a fluid that helps digest fat and carries waste out of the body. Bile travels from the liver cells through a branching network of tubes called bile ducts. The smallest ducts sit in the portal tracts, the small areas where blood enters the liver and bile leaves it.

In primary biliary cholangitis, immune cells attack the cells lining these small bile ducts. Cholangitis means inflammation of the bile ducts. As the ducts are destroyed, bile backs up into the liver, a condition called cholestasis. Over time, the trapped bile and ongoing inflammation can cause scarring, called fibrosis.

What causes primary biliary cholangitis?

Primary biliary cholangitis is an autoimmune disease. Its exact cause is not known. It likely develops when a person with certain inherited immune system genes is exposed to an environmental trigger. It is not contagious and is not caused by alcohol or diet.

People with PBC are more likely to have other autoimmune conditions. Examples include Sjögren syndrome, which causes dry eyes and mouth, systemic sclerosis, and celiac disease.

Who gets primary biliary cholangitis?

Primary biliary cholangitis mainly affects women, who make up about nine out of every ten people with the disease. It is usually diagnosed between the ages of 40 and 60 and is rare in children. It affects about 1 in 10,000 people. In Canada, outside Quebec, about 17,000 people are living with PBC.

What are the symptoms of primary biliary cholangitis?

Many people with primary biliary cholangitis have no symptoms when it is first found. The disease is often discovered because a routine liver blood test panel shows a raised alkaline phosphatase. When symptoms occur, the most common are:

  • Tiredness. Fatigue is common and can be severe, even in early disease.
  • Itching. Itchy skin (pruritus) can be troublesome and is often worse at night.
  • Dry eyes and mouth. These symptoms are usually caused by Sjögren syndrome.

In advanced disease, people may develop yellowing of the skin and eyes (jaundice) and complications of cirrhosis. PBC can also cause bone thinning and high cholesterol.

How is the diagnosis made?

Most people with primary biliary cholangitis are diagnosed with blood tests alone. Doctors look for two main findings:

  • A raised alkaline phosphatase. Alkaline phosphatase (ALP) is a liver enzyme that rises when bile flow is blocked. Gamma-glutamyl transferase (GGT) is usually raised as well.
  • Antimitochondrial antibodies (AMA). These autoantibodies are found in about 95% of people with PBC. They are tested as part of an autoimmune panel. The antibody level does not indicate disease severity.

When both are present, and no other cause is found, doctors can usually diagnose the condition without a biopsy. An ultrasound is often done to make sure the larger bile ducts are not blocked.

A liver biopsy is done when the blood tests are not typical. Examples include people without antimitochondrial antibodies and people who may also have autoimmune hepatitis. A biopsy can also show how much scarring is present.

Microscopic features of primary biliary cholangitis

When a pathologist examines a liver biopsy for primary biliary cholangitis, they focus on the small bile ducts in the portal tracts. The changes are often patchy, so not every portal tract looks the same. Your report may describe some or all of the following features:

  • Florid duct lesion. This is the classic finding in PBC. A small bile duct is surrounded and invaded by immune cells, and the cells lining the duct are injured.
  • Portal inflammation. The portal tracts contain lymphocytes and plasma cells.
  • Granulomas. A granuloma is a small cluster of immune cells called histiocytes. In PBC, granulomas often sit next to damaged bile ducts. They support the diagnosis but are not seen in every biopsy.
  • Bile duct loss. Normally, each portal tract contains a bile duct. When many portal tracts have no duct, pathologists call it ductopenia. The report may give the number or percentage of portal tracts without a duct.
  • Ductular reaction. Small new bile channels form at the edges of the portal tracts as the liver tries to make up for lost ducts.
  • Signs of chronic cholestasis. Liver cells near the portal tracts change when bile has been trapped for a long time. Special stains, such as cytokeratin 7 (CK7) or a copper stain, can highlight these cells.

Some biopsies also show interface hepatitis, in which inflammation spills out of the portal tracts into the nearby liver cells. When this change is marked, the pathologist may comment that features of autoimmune hepatitis are also present. Doctors call this an overlap or variant condition.

The pathologist will also look for features of other diseases that affect the bile ducts. The most important is primary sclerosing cholangitis, which usually affects larger ducts and causes onion-skin scarring around them.

Stage of primary biliary cholangitis

The stage describes how far the disease has progressed in the biopsy. The two most widely used systems, from Ludwig and from Scheuer, divide primary biliary cholangitis into four stages:

  • Stage 1. Inflammation and bile duct damage are limited to the portal tracts.
  • Stage 2. Inflammation spreads from the portal tracts into the nearby liver tissue, and new bile channels form.
  • Stage 3. Bands of scar tissue connect portal tracts.
  • Stage 4. Cirrhosis, with nodules of liver cells surrounded by scar tissue.

Some pathologists use the Nakanuma system instead. It adds separate scores for fibrosis, bile duct loss, and chronic cholestasis to give a stage, and it grades inflammation separately. Because PBC is patchy, different parts of the same liver can be at different stages. A small biopsy may therefore underestimate or overestimate the stage.

What does primary biliary cholangitis mean for my health?

The outlook for primary biliary cholangitis has improved greatly with treatment. A large international study followed people treated with ursodeoxycholic acid. Those whose liver tests became normal did as well as, or better than, people of the same age and sex without PBC. About 20% to 40% of people do not respond well enough to ursodeoxycholic acid alone. These people have a higher risk of the disease progressing and are offered additional treatment.

People with PBC have a small increased risk of hepatocellular carcinoma, a type of liver cancer. In one Dutch study of treated patients, about 0.2% developed liver cancer each year. The risk is higher in men, in people with cirrhosis, and in people who do not respond to treatment.

What happens after the diagnosis?

After a diagnosis of primary biliary cholangitis, treatment usually starts right away and continues for life. A hepatologist, a doctor who specializes in the liver, often leads care.

  • First treatment. Ursodeoxycholic acid, also called UDCA or ursodiol, is the standard first medication. It is a natural bile acid taken by mouth that helps bile flow. Your doctor will check your blood tests after about a year to see how well it is working.
  • Second treatment. People who do not respond well enough to UDCA, or who cannot take it, may be offered a second medication. These are described below.
  • Symptom treatment. Itching and fatigue are treated separately, because they do not always improve with the medications that slow the disease.
  • Bone health. Your doctor may check your bone density and recommend calcium and vitamin D.
  • Liver cancer screening. People with cirrhosis are offered regular ultrasounds to look for early liver cancer.
  • Liver transplant. A transplant is an option for people with advanced cirrhosis or liver failure.

Two newer medications are approved for people who do not respond to UDCA or cannot tolerate it. Both are taken by mouth, usually together with UDCA.

  • Elafibranor. The US Food and Drug Administration (FDA) granted accelerated approval in June 2024, and the European Union granted conditional approval in September 2024. Health Canada authorized it with conditions in April 2025.
  • Seladelpar. This medication received FDA accelerated approval in August 2024 and conditional approval in the European Union in February 2025. Health Canada authorized it with conditions in October 2025.

These approvals are based on improvements in alkaline phosphatase and other blood tests. Studies to confirm whether they prevent cirrhosis and improve survival are still underway.

An older second-line medication, obeticholic acid, is no longer available in some countries. The European Medicines Agency revoked its authorization in August 2024. It was withdrawn from the US market in September 2025 at the FDA’s request because of concerns about serious liver injury. A Canadian drug review published in 2026 still listed it among treatments used in Canada. If you take obeticholic acid, ask your doctor whether you should continue it.

Questions to ask your doctor

  • Was my diagnosis made with blood tests, a biopsy, or both?
  • Were antimitochondrial antibodies found in my blood?
  • What stage was reported in my biopsy?
  • Was there evidence of bile duct loss?
  • Did my biopsy show features of autoimmune hepatitis as well?
  • How will we know whether ursodeoxycholic acid is working for me?
  • Would I benefit from a second medication, such as elafibranor or seladelpar?
  • What can be done for my itching or fatigue?
  • Should I have a bone density test?
  • Do I need screening for liver cancer?
  • Should I be tested for other autoimmune conditions?

Related articles on MyPathologyReport.com

A+ A A-
Was this article helpful?